Literature DB >> 21518784

Leishmania-infected macrophages are targets of NK cell-derived cytokines but not of NK cell cytotoxicity.

Chittappen K Prajeeth1, Simone Haeberlein, Heidi Sebald, Ulrike Schleicher, Christian Bogdan.   

Abstract

Natural killer (NK) cells are important components of a protective immune response against intracellular pathogens such as Leishmania parasites, which reside within myeloid cells. Previous in vivo studies in murine cutaneous or visceral leishmaniasis showed that NK cells are activated by conventional dendritic cells in a Toll-like receptor 9-, interleukin-12 (IL-12)-, and IL-18-dependent manner during the early phase of infection and help to restrict the tissue parasite burden by unknown mechanisms. Here, we tested whether NK cells contribute to the control of Leishmania infections by lysing or by activating infected host cells. Coculture experiments revealed that activated NK cells from poly(I:C)-treated mice readily killed tumor target cells, whereas Leishmania infantum- or L. major-infected macrophages or dendritic cells remained viable. Infection with Leishmania did not significantly alter the expression of NK cell-activating molecules (retinoic acid early transcript alpha [Rae-1α], mouse UL16-binding protein-like transcript 1 [MULT-1], CD48) or inhibitory molecules (major histocompatibility complex [MHC] class I, nonclassical MHC class 1b molecule Qa-1) on the surface of myeloid cells, which offers an explanation for their protection from NK cell cytotoxicity. Consistent with these in vitro data, in vivo cytotoxicity assays revealed poor cytolytic activity of NK cells against adoptively transferred infected wild-type macrophages, whereas MHC class I-deficient macrophages were efficiently eliminated. NK cells activated by IL-12 and IL-18 stimulated macrophages to kill intracellular Leishmania in a cell contact-independent but gamma interferon-, tumor necrosis factor-, and inducible nitric oxide synthase-dependent manner. We conclude that Leishmania parasites, unlike viruses, do not render infected myeloid cells susceptible to the cytotoxicity of NK cells. Instead, soluble products of NK cells trigger the leishmanicidal activity of macrophages.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21518784      PMCID: PMC3191990          DOI: 10.1128/IAI.00079-11

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  78 in total

1.  Unidirectional signaling triggered through 2B4 (CD244), not CD48, in murine NK cells.

Authors:  Eun-Ok Kim; Nayoung Kim; Tae-Jin Kim; Kwanghee Kim; Tae Woo Kim; Vinay Kumar; Kyung-Mi Lee
Journal:  J Leukoc Biol       Date:  2010-07-20       Impact factor: 4.962

2.  Innate immune defense in visceral leishmaniasis: cytokine mediated protective role by allogeneic effector cell.

Authors:  Partha Pratim Manna; Ganes Chakrabarti; Santu Bandyopadhyay
Journal:  Vaccine       Date:  2009-10-29       Impact factor: 3.641

3.  Natural killer cells support the induction of protective immunity during dendritic cell-mediated vaccination against Leishmania major.

Authors:  Katharina A Remer; Bianca Roeger; Christine Hambrecht; Heidrun Moll
Journal:  Immunology       Date:  2010-12       Impact factor: 7.397

4.  Primed antigen-specific CD4+ T cells are required for NK cell activation in vivo upon Leishmania major infection.

Authors:  Franck Bihl; Julien Pecheur; Béatrice Bréart; Gwenola Poupon; Julie Cazareth; Valérie Julia; Nicolas Glaichenhaus; Véronique M Braud
Journal:  J Immunol       Date:  2010-07-12       Impact factor: 5.422

5.  Leukocytes infiltrate the skin and draining lymph nodes in response to the protozoan Leishmania infantum chagasi.

Authors:  Colin J Thalhofer; Yani Chen; Bayan Sudan; Laurie Love-Homan; Mary E Wilson
Journal:  Infect Immun       Date:  2010-10-11       Impact factor: 3.441

Review 6.  Modulation of natural killer cell activity by viruses.

Authors:  Vanda Juranić Lisnić; Astrid Krmpotić; Stipan Jonjić
Journal:  Curr Opin Microbiol       Date:  2010-06-16       Impact factor: 7.934

7.  IL-18, but not IL-15, contributes to the IL-12-dependent induction of NK-cell effector functions by Leishmania infantum in vivo.

Authors:  Simone Haeberlein; Heidi Sebald; Christian Bogdan; Ulrike Schleicher
Journal:  Eur J Immunol       Date:  2010-06       Impact factor: 5.532

8.  Cytomegalovirus immunoevasin reveals the physiological role of "missing self" recognition in natural killer cell dependent virus control in vivo.

Authors:  Marina Babić; Michal Pyzik; Biljana Zafirova; Maja Mitrović; Višnja Butorac; Lewis L Lanier; Astrid Krmpotić; Silvia M Vidal; Stipan Jonjić
Journal:  J Exp Med       Date:  2010-11-15       Impact factor: 14.307

9.  IL-22 produced by human NK cells inhibits growth of Mycobacterium tuberculosis by enhancing phagolysosomal fusion.

Authors:  Rohan Dhiman; Mohanalaxmi Indramohan; Peter F Barnes; Ramesh C Nayak; Padmaja Paidipally; L Vijaya Mohan Rao; Ramakrishna Vankayalapati
Journal:  J Immunol       Date:  2009-10-28       Impact factor: 5.422

10.  Activating receptors promote NK cell expansion for maintenance, IL-10 production, and CD8 T cell regulation during viral infection.

Authors:  Seung-Hwan Lee; Kwang-Sin Kim; Nassima Fodil-Cornu; Silvia M Vidal; Christine A Biron
Journal:  J Exp Med       Date:  2009-08-31       Impact factor: 14.307

View more
  19 in total

1.  Leishmania (Viannia) shawi purified antigens confer protection against murine cutaneous leishmaniasis.

Authors:  Luiz Felipe Domingues Passero; Ana Kely Carvalho; Maria Luiza A C Bordon; Alexis Bonfim-Melo; Marcos Hikari Toyama; Carlos Eduardo Pereira Corbett; Márcia Dalastra Laurenti
Journal:  Inflamm Res       Date:  2011-12-14       Impact factor: 4.575

2.  Differential effects of stimulatory factors on natural killer cell activities of young and aged mice.

Authors:  Shoko Nogusa; Donna M Murasko; Elizabeth M Gardner
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2012-03-27       Impact factor: 6.053

3.  Mechanisms of immune evasion in leishmaniasis.

Authors:  Gaurav Gupta; Steve Oghumu; Abhay R Satoskar
Journal:  Adv Appl Microbiol       Date:  2013       Impact factor: 5.086

Review 4.  Memory T cells in cutaneous leishmaniasis.

Authors:  Nelson D Glennie; Phillip Scott
Journal:  Cell Immunol       Date:  2016-07-16       Impact factor: 4.868

Review 5.  Redundant and regulatory roles for Toll-like receptors in Leishmania infection.

Authors:  P Chauhan; D Shukla; D Chattopadhyay; B Saha
Journal:  Clin Exp Immunol       Date:  2017-08-07       Impact factor: 4.330

6.  Granzyme B Produced by Natural Killer Cells Enhances Inflammatory Response and Contributes to the Immunopathology of Cutaneous Leishmaniasis.

Authors:  Taís M Campos; Fernanda O Novais; Maíra Saldanha; Rúbia Costa; Morgana Lordelo; Daniela Celestino; Camilla Sampaio; Natália Tavares; Sérgio Arruda; Paulo Machado; Cláudia Brodskyn; Phillip Scott; Edgar M Carvalho; Lucas P Carvalho
Journal:  J Infect Dis       Date:  2020-03-02       Impact factor: 5.226

7.  TNF-Mediated Restriction of Arginase 1 Expression in Myeloid Cells Triggers Type 2 NO Synthase Activity at the Site of Infection.

Authors:  Ulrike Schleicher; Katrin Paduch; Andrea Debus; Stephanie Obermeyer; Till König; Jessica C Kling; Eliana Ribechini; Diana Dudziak; Dimitrios Mougiakakos; Peter J Murray; Renato Ostuni; Heinrich Körner; Christian Bogdan
Journal:  Cell Rep       Date:  2016-04-21       Impact factor: 9.423

8.  Macrophages help NK cells to attack tumor cells by stimulatory NKG2D ligand but protect themselves from NK killing by inhibitory ligand Qa-1.

Authors:  Zhixia Zhou; Cai Zhang; Jian Zhang; Zhigang Tian
Journal:  PLoS One       Date:  2012-05-18       Impact factor: 3.240

Review 9.  Natural killer cells in experimental and human leishmaniasis.

Authors:  Christian Bogdan
Journal:  Front Cell Infect Microbiol       Date:  2012-05-29       Impact factor: 5.293

10.  Evaluation of FcγRIIIB-NA1/NA2 Polymorphism in Visceral Leishmaniasis.

Authors:  Mohammad Abasi; Pegah Lotfi; Ahad Bazmani; Mohamad Matini; Mehrdad Hajilooi
Journal:  Iran Red Crescent Med J       Date:  2014-04-05       Impact factor: 0.611

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.